A Study of BTX-1188 in Subjects With Advanced Malignancies

Summary

This is a multicenter, open label, nonrandomized, sequential dose escalation, multiple dose study designed to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-1188 orally administered in subjects with advanced malignancies.

Timeline

Start

2022-01-24

Primary completion

2023-09-12

Completion

2023-09-12

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

Indications